ArticleBiomolecules & biomedicine2026
Regulatory B cells and
Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular Mechanisms and Immune Regulation in Prostate Cancer: A Review.International journal of molecular sciences · 2026Review
- cGAS-STING pathway regulated by spatiotemporal heterogeneity of tumor microenvironment and precision therapy strategies in lung cancer.Journal of experimental & clinical cancer research : CR · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is among the most prevalent malignancies affecting men globally. The immunosuppressive characteristics of the tumor microenvironment significantly hinder the effectiveness of immunotherapeutic strategies. B cells have a dual role in immune responses, with regulatory B cells (Bregs) promoting immune tolerance through the secretion of immunosuppressive cytokines, facilitating tumor immune evasion. However, the specific role of Bregs in prostate cancer remains inadequately understood. In this study, we systematically identified Breg subpopulations in prostate cancer using single-cell RNA sequencing (scRNA-seq), multi-omics analysis, and machine learning techniques, while also investigating their association with clinical prognosis. Our analysis revealed that increased infiltration of Bregs is strongly correlated with shorter biochemical recurrence-free survival (BCRFS). Additionally, higher expression levels of SIVA1 apoptosis-inducing factor (SIVA1) were positively associated with the immune checkpoint lymphocyte-activation gene 3 (LAG3). Utilizing Breg-related prognostic genes (BRPGs), we developed a novel model for predicting BCRFS, which we validated across multiple independent cohorts. Further immunohistochemical analysis confirmed the positive correlation between elevated SIVA1 expression and poor prognosis, as well as its association with LAG3. Collectively, these findings provide new insights into the immune microenvironment of prostate cancer and suggest that Breg-related characteristics and the SIVA1-LAG3 relationship in tumor cells may represent promising therapeutic targets for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.